Cargando…

Stakeholder Views on the Idea of Medicines Reuse in the UK

People’s views about medicines reuse are being examined in a handful of qualitative studies and this commentary adds to that work by drawing on our own discussions with groups of stakeholders in the UK in the past two years. The reuse of medicines within the community pharmacy setting is not permitt...

Descripción completa

Detalles Bibliográficos
Autores principales: Donyai, Parastou, McCrindle, Rachel, Hui, Terence K. L., Sherratt, R. Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167662/
https://www.ncbi.nlm.nih.gov/pubmed/33923745
http://dx.doi.org/10.3390/pharmacy9020085
_version_ 1783701741071499264
author Donyai, Parastou
McCrindle, Rachel
Hui, Terence K. L.
Sherratt, R. Simon
author_facet Donyai, Parastou
McCrindle, Rachel
Hui, Terence K. L.
Sherratt, R. Simon
author_sort Donyai, Parastou
collection PubMed
description People’s views about medicines reuse are being examined in a handful of qualitative studies and this commentary adds to that work by drawing on our own discussions with groups of stakeholders in the UK in the past two years. The reuse of medicines within the community pharmacy setting is not permitted in the UK but our multidisciplinary team anticipates that this position will change in the coming years as medication shortages and worries about environmental waste and financial losses from the destruction of unused medicines are brought to the fore. Indeed, for many stakeholders, the issue of waste is a strong feature of conversations about medicines reuse. In addition to this, stakeholders identify the numerous barriers to medicines reuse in the UK. This includes the current uncertainty about the quality of unused medicines returned to pharmacies, which could otherwise be reused. However, stakeholders have also been very willing to propose solutions to a range of existing barriers. Our commentary draws on stakeholder meetings to elaborate the range of views about medicines reuse within a UK context. The challenge is to move forward from these views to advance the technologies that will facilitate medicines reuse practically as well as legally.
format Online
Article
Text
id pubmed-8167662
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81676622021-06-02 Stakeholder Views on the Idea of Medicines Reuse in the UK Donyai, Parastou McCrindle, Rachel Hui, Terence K. L. Sherratt, R. Simon Pharmacy (Basel) Commentary People’s views about medicines reuse are being examined in a handful of qualitative studies and this commentary adds to that work by drawing on our own discussions with groups of stakeholders in the UK in the past two years. The reuse of medicines within the community pharmacy setting is not permitted in the UK but our multidisciplinary team anticipates that this position will change in the coming years as medication shortages and worries about environmental waste and financial losses from the destruction of unused medicines are brought to the fore. Indeed, for many stakeholders, the issue of waste is a strong feature of conversations about medicines reuse. In addition to this, stakeholders identify the numerous barriers to medicines reuse in the UK. This includes the current uncertainty about the quality of unused medicines returned to pharmacies, which could otherwise be reused. However, stakeholders have also been very willing to propose solutions to a range of existing barriers. Our commentary draws on stakeholder meetings to elaborate the range of views about medicines reuse within a UK context. The challenge is to move forward from these views to advance the technologies that will facilitate medicines reuse practically as well as legally. MDPI 2021-04-16 /pmc/articles/PMC8167662/ /pubmed/33923745 http://dx.doi.org/10.3390/pharmacy9020085 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Donyai, Parastou
McCrindle, Rachel
Hui, Terence K. L.
Sherratt, R. Simon
Stakeholder Views on the Idea of Medicines Reuse in the UK
title Stakeholder Views on the Idea of Medicines Reuse in the UK
title_full Stakeholder Views on the Idea of Medicines Reuse in the UK
title_fullStr Stakeholder Views on the Idea of Medicines Reuse in the UK
title_full_unstemmed Stakeholder Views on the Idea of Medicines Reuse in the UK
title_short Stakeholder Views on the Idea of Medicines Reuse in the UK
title_sort stakeholder views on the idea of medicines reuse in the uk
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167662/
https://www.ncbi.nlm.nih.gov/pubmed/33923745
http://dx.doi.org/10.3390/pharmacy9020085
work_keys_str_mv AT donyaiparastou stakeholderviewsontheideaofmedicinesreuseintheuk
AT mccrindlerachel stakeholderviewsontheideaofmedicinesreuseintheuk
AT huiterencekl stakeholderviewsontheideaofmedicinesreuseintheuk
AT sherrattrsimon stakeholderviewsontheideaofmedicinesreuseintheuk